Dr. Paul M Ridker, MD (Harvard Medical School 1985), MPH (Harvard School of Public Health 1990), serves as the Eugene Braunwald Professor of Medicine at the Harvard Medical School and as Director of the Center for Cardiovascular Disease Prevention at the Brigham and Women’s Hospital in Boston Massachusetts USA. Over a 30 year period of focused translational research, Dr. Ridker and his collaborators provided the first proof-of-principle for the inflammation hypothesis of atherothrombosis in humans, the first FDA-approved diagnostic test for vascular inflammation (hsCRP), and the first proven anti-inflammatory treatment for heart disease. Dr. Ridker’s clinical, epidemiologic, and translational work in innate immunity has provided the first hard evidence in 40 years of an effective therapy for atherosclerosis not directly related to cholesterol reduction, blood pressure, or coagulation.
Dr. Ridker is also known internationally for his leadership of over 15 major multi-national randomized clinical trial including PREVENT, JUPITER, SPIRE, CANTOS, CIRT, PROMINENT, and ZEUS. The recipient of multiple honorary degrees and international awards, Dr. Ridker is a Distinguished Scientist of the American Heart Association and an elected member of the National Academy of Sciences, USA. With an h-index of 248 and over 366,000 cumulative citations, Dr. Ridker has long been among the most influential cardiovascular researchers worldwide.

Dr. Ridker makes the following disclosures:

Consultant Fees/Honoraria:  Agepha, AstraZeneca, Boston Pharma, Civi Biopharma, Corvidia, Flame, Inc., IQVIA, Janssen Pharmaceuticals, Novartis, Novo Nordisk, Omeicos, Simanomics, Health Outlook.

Research/Research Grants:  Amarin, Kowa Pharmaceuticals, Novartis.